Ruian Gene's first quarter report: Research and development intensity increased against the trend to 25.46%, and operating cash flow continued to make positive contributions.

Against the background of continued competition in the field of in vitro diagnostics and the slower-than-expected recovery of end demand, Riong Gene disclosed its first quarter report for 2026 on the evening of April 27. During the reporting period, the company achieved operating income of 35.8641 million yuan, a slight decrease compared to the same period last year, but a deeper analysis of its financial structure reveals that the company still demonstrates strong fundamental resilience in key dimensions such as expense control, research and development investment intensity, and operating cash flow. The quarterly report shows that, despite pressure on revenue, Riong Gene implemented precise structural adjustments to operating expenses during the period.